Core Viewpoint - PainReform's acquisition of DeepSolar positions the company as a potential leader in the high-growth, high-margin AI solar energy management sector while maintaining its focus on pharmaceutical innovation [1][4]. Company Overview - PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics, particularly in post-surgical pain relief [9]. - The company has successfully acquired 100% of DeepSolar, an AI-driven solar analytics platform, from BladeRanger Ltd [1][2]. Acquisition Details - The acquisition allows PainReform to enter the clean energy sector, leveraging DeepSolar's software to optimize solar farm efficiency and profitability [2]. - DeepSolar's AI analytics platform enhances energy production and reduces operational inefficiencies, integrating with SCADA systems for monitoring and predictive maintenance [3][6]. - The transaction involved PainReform issuing 178,769 ordinary shares and 223,792 pre-funded warrants to BladeRanger Ltd as part of the acquisition [7]. Market Potential - The solar energy market is projected to grow at an annual rate of 25.32%, generating over 1 terawatt (TW) of energy from 2021 to 2026 [3]. - The residential solar market reached a valuation of $94.2 billion in 2024 and is expected to grow at 8% annually through 2034 [3]. Strategic Goals - PainReform aims to broaden DeepSolar's customer base, targeting utility-scale solar operators, independent power producers, and residential solar users [2]. - The company plans to explore strategic partnerships with utility companies, solar technology providers, and smart grid operators to drive revenue growth [4][5]. - DeepSolar's SaaS model is expected to generate steady, high-margin revenue streams while reducing operational costs for customers by up to 30% [6]. Technological Differentiation - DeepSolar's AI capabilities provide a competitive advantage in the renewable energy market, positioning PainReform as a potential technology leader in solar asset optimization [6].

Core Viewpoint - PainReform Ltd. has announced a strategic acquisition of DeepSolar, an AI-driven solar analytics platform, which is expected to enhance its growth potential while maintaining its commitment to pharmaceutical innovation [1][5][12]. Company Overview - PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics, particularly in pain management [14]. - DeepSolar is an AI-powered analytics company that optimizes the efficiency and profitability of solar energy assets through proprietary software and automation tools [2][3]. Acquisition Details - The acquisition agreement includes the transfer of all rights, intellectual property, customer relations, and the "My DeepSolar" application to PainReform [6][11]. - In exchange, BladeRanger Ltd. will receive 178,769 ordinary shares of PainReform, representing 9.9% of its issued share capital, along with various warrants [7][8]. Market Opportunity - The global residential solar market was valued at $94.2 billion in 2024 and is projected to grow at an annual rate of 8% until 2034 [15]. - DeepSolar's technology can reduce operational costs by up to 30%, significantly improving profitability for solar asset owners [3][15]. Strategic Rationale - The acquisition is seen as a unique opportunity for PainReform to enter a high-margin, rapidly growing sector, leveraging DeepSolar's advanced AI capabilities to enhance solar energy efficiency [5][12]. - PainReform aims to capitalize on the technological advantages of DeepSolar to position itself for long-term growth while continuing its focus on pharmaceutical innovation [12][13].

Core Viewpoint - PainReform Ltd. announced that its Phase 3 clinical trial for PRF-110 in post-surgical pain management did not meet the primary endpoint due to unclear data from the final 24-hour period, but the company is initiating R&D activities to refine the drug's pharmacokinetics and pharmacodynamics [2][6][7] Group 1: Clinical Trial Update - The Phase 3 clinical trial initially reported statistically significant superiority of PRF-110 over placebo in reducing pain during the first 48 hours post-surgery [6] - The final 24-hour data was unclear, preventing the study from meeting its primary endpoint of a 72-hour follow-up [2][6] - The company is focused on resolving the data issues through high-level in-vitro models before proceeding with additional clinical work [7] Group 2: Product Information - PRF-110 is based on the local anesthetic ropivacaine and is designed for postoperative pain relief [7] - The product features an oil-based, viscous solution that is applied directly into the surgical wound to provide localized and extended analgesia [7] - The proprietary extended-release drug-delivery system aims to reduce the need for repeated doses and minimize opioid use [7] Group 3: Future Directions - The company is committed to leveraging learnings from the trial to enhance PRF-110's profile for future evaluations [7] - Ongoing R&D efforts are aimed at deepening the understanding of PRF-110's pharmacological properties [7] - PainReform is also reviewing its strategic options, although there is no assurance that this will lead to enhanced shareholder value [7]

Core Insights - PainReform Ltd. has received partial topline data from its Phase 3 clinical trial for PRF-110, which is aimed at managing post-surgical pain in patients undergoing bunionectomy [1][2] - Initial analysis shows PRF-110 has statistically significant superiority over placebo in reducing pain during the first 48 hours post-surgery, indicating its potential effectiveness [2][4] - There are unresolved data issues regarding the subsequent 24-hour period, which is critical for assessing the primary endpoint of the trial [3] Company Overview - PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics, with PRF-110 being its lead product based on ropivacaine [6] - PRF-110 is designed to provide prolonged pain relief while minimizing the need for opioids, potentially enhancing patient recovery and safety in post-surgical settings [4][6] Clinical Trial Details - The Phase 3 trial is a randomized, double-blind, placebo- and active-controlled study involving 428 patients, with PRF-110 administered intra-operatively [5] - The primary efficacy endpoint is the mean area under the curve (AUC) of pain intensity scores over 72 hours, with secondary endpoints including opioid consumption and the proportion of opioid-free subjects [5]

Core Viewpoint - PainReform Ltd. has received a notification from Nasdaq indicating it no longer meets the minimum stockholders' equity requirement for continued listing, but this has no immediate effect on its trading status [1][2]. Company Overview - PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics, with its lead product PRF-110 targeting postoperative pain relief [3]. - PRF-110 is an oil-based, viscous solution designed for direct application into surgical wounds to provide localized and extended pain relief, potentially reducing the need for opiates [3]. Nasdaq Notification Details - The company has 45 days from the notification date to submit a plan to regain compliance with the Minimum Equity Rule or an alternative listing standard, with a deadline of December 19, 2024 [2]. - If the plan is accepted, Nasdaq may grant an extension of up to 180 days, allowing compliance to be achieved by May 3, 2025 [2].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant's name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Washington, D.C. 2 ...

Core Insights - PainReform Ltd. announced positive findings regarding the compatibility of its lead product PRF-110 with surgical sutures in human clinical trials, indicating its potential for extended, non-opiate post-surgical pain relief [1][4] Group 1: Product and Clinical Trials - PRF-110 is designed to provide extended post-surgical pain relief without the use of opiates, utilizing a proprietary extended-release drug-delivery system [5] - Comprehensive in vitro studies were conducted to assess the impact of PRF-110 on both nonabsorbable (PROLENE™) and resorbable (Vicryl™) sutures, focusing on mechanical properties such as breaking force and elongation [2] - Results showed that PRF-110 does not affect the mechanical properties of either type of suture, suggesting compatibility with surgical conditions [3] Group 2: Company Leadership and Future Directions - Ehud Geller, Chairman and interim CEO, emphasized the importance of these findings as a milestone for the safety and efficacy of PRF-110, advancing the product toward commercialization [4] - The ability to provide extended pain relief without compromising suture integrity is highlighted as a significant advancement in post-surgical care [4]

Core Viewpoint - PainReform Ltd. has entered into definitive agreements for the immediate exercise of outstanding warrants, allowing the purchase of up to 989,300 ordinary shares at a reduced exercise price of $1.60 per share, down from $4.80 per share [1][2]. Group 1: Financial Details - The gross proceeds from the exercise of the warrants are expected to be approximately $1.58 million, prior to deducting placement agent fees and estimated offering expenses [3]. - The company intends to use the net proceeds from the offering for general corporate purposes [3]. Group 2: New Warrants - In exchange for the immediate exercise of the warrants, the company will issue new unregistered warrants to purchase up to 1,978,600 ordinary shares, with an exercise price of $1.60 per share, exercisable immediately upon issuance and expiring five years from the date of issuance [2]. Group 3: Regulatory Information - The new warrants were offered in a private placement and have not been registered under the Securities Act of 1933, meaning they cannot be offered or sold in the U.S. without registration or an applicable exemption [4]. - The company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants [4]. Group 4: Company Overview - PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics, with its lead product PRF-110 targeting postoperative pain relief [6]. - PRF-110 is based on the local anesthetic ropivacaine and is designed to provide localized and extended postoperative analgesia without the need for repeated doses [6].

Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX | | Page | | --- | --- | | Condensed Balance Sheets | F-2 | | Condensed Statements of Comprehensive Loss | F-3 | | Condensed Statements of Changes in Shareholders' (Deficit) Equity | F-4 | | Condensed Statements of Cash Flows | F-5 | | Notes to Condensed Financial Statements | F-6 - F-12 | PAINREFORM LTD. CONDENSED BALANCE SHEETS (Unaudited) U.S. dollars in thousands U.S. dollars in thou ...

TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced compelling safety data for its lead product candidate, PRF-110. This data, derived from pharmacokinetic (PK) studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110's promising safety profile, with maximum blood levels (Cmax) recorded at approxi ...